HEALTH and regulatory officials on Monday said they would investigate allegations that doctor-investors at Bell-Kenz Pharma Inc. were prescribing hypertension and diabetes medication that the company imports as the Senate begins hearings on the controversy today.
Officials from the Department of Health (DoH), the Professional Regulation Commission (PRC), and the Food and Drug Administration (FDA) said they would jointly investigate reports of a "pyramiding" scheme at the company and the use of luxurious gifts to entice doctors to prescribe their products.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.